Ezetimibe improves postprandial hyperlipidaemia in patients with type IIb hyperlipidaemia

Abstract

These findings suggest that ezetimibe improves fasting lipoprotein profiles and postprandial hyperlipidaemia by suppressing intestinal CM production in patients with type IIb hyperlipidaemia and such treatment may prove to be effective in reducing atherosclerosis.